Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

The Replimune acceptance matters beyond one drug. RP1 received two complete response letters from the FDA. Two rejections. Most companies would have shelved the program. Instead, Replimune resubmitted, and the FDA accepted the filing with a response target of August 2026. BioPharma Dive framed this as part of a broader pattern: the FDA under acting leadership appears to be reconsidering some of the more aggressive regulatory positions taken during the Makary era. The UniQure Huntington's reversal, the REGENXBIO Duchenne filing acceptance, and now the RP1 resubmission all point in the same direction. Whether this represents a genuine philosophical shift or simply the absence of a strong commissioner pushing a particular agenda is an open question. But for companies with programs that were rejected or delayed over the past year, the signal is clear: resubmit. The door may be more open than it was. On a completely different front, the EU is having a rough week in pharma governance. The CHMP recommended pulling Tavneos off the European market (matching the FDA's voluntary removal request). And the European Commission opened an antitrust case against Sanofi for allegedly disparaging a competitor's flu vaccine. Two different regulatory actions, two different companies, both reflecting the increasing scrutiny of pharma behavior on both sides of the Atlantic. 👉 Read Full Analysis

🔮 What To Watch

🔬 Regulatory

FDA Accepts Replimune RP1 BLA Resubmission for Melanoma REPL

The FDA accepted Replimune's resubmitted BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma on June 26, with a response expected by August 2026, according to RTTNews. RP1 is an oncolytic immunotherapy designed to selectively replicate in and destroy tumor cells while stimulating an anti-tumor immune response. The drug received two previous CRLs from the FDA. BioPharma Dive noted the acceptance is "the latest example of changing attitudes at the FDA" and part of a broader pattern that includes the UniQure Huntington's reversal and the REGENXBIO Duchenne filing.

📊 Capital Markets

Definium Raises $805M in Upsized Offering After Phase 3 MDD Win

Definium Therapeutics closed an upsized public offering raising $805M in gross proceeds on June 26, according to The Pharma Letter. The offering came days after the company reported positive Phase 3 data for DT120, an orally disintegrating tablet for major depressive disorder, which sent shares up 52%. The raise is one of the largest follow on offerings by a clinical stage biotech in 2026 and reflects investor confidence in the MDD data and the commercial potential of a differentiated dosage form in the largest CNS market.

$450M in Venture Funding in a Single Week

BioPharma Dive reported that five privately held biotech companies announced a combined $450M in venture funding during the week ending June 25, one of the busiest weeks for fundraising since April. The pace of venture investment, combined with the IPO window (13 companies, $4.1B+), underscores the health of the private biotech capital markets heading into H2.

🌍 EU Regulatory

CHMP Recommends Tavneos Marketing Authorization Be Revoked

The European CHMP recommended revoking the marketing authorization for Amgen's Tavneos (avacopan) for ANCA associated vasculitis, according to BioPharma Dive. This follows the FDA's call for voluntary removal over patient deaths, which we covered on June 17. The dual regulatory action on both sides of the Atlantic is unusual and reflects serious safety concerns. Amgen's Duke independent analysis, commissioned to defend the drug's safety profile, apparently did not convince European regulators.

EU Opens Antitrust Investigation into Sanofi Flu Vaccine Campaign

The European Commission opened a formal antitrust investigation into whether Sanofi breached EU competition rules by disparaging the only rival flu vaccine recommended for vulnerable patients with risk factors, according to The Pharma Letter. The investigation adds to the regulatory pressure facing Sanofi, which is also navigating the riliprubart Phase 3 failure in CIDP and the upcoming Dupixent patent cliff.

🔬 Diagnostics

DeepHealth Receives FDA Clearances for AI Breast Imaging Tools

DeepHealth received FDA clearances for new AI powered breast imaging tools on June 25, according to RTTNews. The clearances add to the growing portfolio of AI diagnostics receiving regulatory approval across radiology, pathology (Roche/PathAI partnership from May), and liquid biopsy (Natera Signatera companion diagnostic from May 15). AI in diagnostics is one of the fastest growing areas in medtech.

📋 The Week in Review

📅 Catalyst Calendar

👉 Read Full Analysis

Three regulatory reversals in three weeks tell a consistent story:

UniQure (June 17): FDA reversed its demand for additional trial data and accepted the Huntington's gene therapy filing for accelerated approval.

REGENXBIO (June 25): Completed dosing for AFFINITY DUCHENNE and is on track for Q3 BLA filing. BioSpace reported the company is "planning to test the agency's apparent newfound rare disease outlook."

Replimune (June 26): After two CRLs, the FDA accepted the RP1 BLA resubmission with an August response target.

BioPharma Dive wrote that these decisions reflect "changing attitudes at the FDA" and noted they follow the exits of Makary and Prasad. The acting leadership, which includes Michael Davis at CDER and Karim Mikhail at CBER, appears to be taking a less confrontational approach to borderline applications.

For companies with programs that were rejected, delayed, or subject to unexpected FDA demands over the past 18 months: the environment may have shifted. The data requirements have not changed, but the willingness to engage constructively on filing strategies appears to have improved.

💊 Medicare Bridge: What Wednesday Looks Like

The Medicare GLP-1 Bridge program launches July 1. Key details:

Initial enrollment volume in the first week will be the most watched data point in the GLP-1 space. Analysts estimate 500,000 to 1 million Medicare beneficiaries could enroll in the first quarter. The program was a core component of the MFN pricing framework negotiated earlier this year.

📊 H1 2026: Where We Stand

As we enter the final week of H1 2026:

The second half starts this week.

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →